Fig 4.
Drug-related, nonhematologic adverse events (AEs) reported in ≥ 10% of patients. Odds ratios (dasatinib v imatinib) with 95% CIs are shown for AEs that occurred in ≥ 10% of patients. Blue favors dasatinib, and gold favors imatinib.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.